EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting mitochondrial dysfunction to quell neuroinflammation in central nervous system (CNS): a new strategy for treating CNS disease with nanomedicines

Shuya Wang, Min Liu, Xiaojing Shi, Tingli Xiong, Ruishi Li, Wenxuan Zheng, Qiong Huang, Yayun Nan, Kelong Ai

Science Bulletin · 2026-06 · 71 (12) · 3158-3195

DOI: 10.1016/j.scib.2026.05.020 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Science Bulletin, 2026-06. Verfasst von Shuya Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, China; Xiangya School of Pharmaceutical Sciences, Central South …. Hauptthemen laut MEDLINE: Mitochondria, Nanomedicine, Central Nervous System Diseases, Neuroinflammatory Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 532 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Central South University, Natural Science Foundation of Ningxia Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuroinflammation has emerged as an important pathogenic factor in central nervous system (CNS) disease, including various neurodegenerative diseases, brain injuries, and autoimmune conditions, affecting approximately 3 billion people worldwide. Mitochondrial dysfunction within neurovascular unit (NVU) cells not only initiates neuronal damage and blood-brain barrier (BBB) disruption but also critically reprograms immunometabolism, shifting microglia and infiltrating immune cells toward a pro-inflammatory, glycolysis-dominant state while impairing anti-inflammatory, oxidative phosphorylation-dependent functions. This metabolic rewiring fuels a vicious, self-amplifying cycle between mitochondrial impairment and sustained neuroinflammation. Consequently, targeting mitochondrial dysfunction has therefore emerged as a promising therapeutic strategy for controlling neuroinflammation. However, the double-membrane structure of mitochondria, coupled with the restrictive BBB, imposes formidable barriers to therapeutic delivery. Nanomedicine offers unprecedented opportunities. Advanced nanodrugs, engineered with mitochondrial-targeting ligands, stimuli-responsive materials, or biomimetic coatings, enable precise delivery of therapeutics directly to impaired mitochondria within the CNS. This review summarizes recent advances in mitochondrial dysfunction-induced neuroinflammation, highlights emerging nanotechnology-based mitochondrial targeting strategies in various CNS diseases, and discusses the existing challenges and future perspectives for translating these approaches into effective CNS therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MitochondriaNanomedicineCentral Nervous System DiseasesNeuroinflammatory DiseasesHumansAnimalsBlood-Brain BarrierCentral Nervous SystemDrug Delivery Systems

Stichwörter der Autor:innen

Blood-brain barrierCentral nervous systemMitochondriaNanomedicinesNeuroinflammation

Autor:innen und Institutionen

  • Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, China; Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410078, China.
  • Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410078, China; Hunan Provincial Key Laboratory of Cardiovascular Research, Xiangya School of Pharmaceutical Sciences, Central South Universit…
  • Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China;…
  • Geriatric Medical Center, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan 750002, China. Electronic address: nanyy_2009@163.com.

Förderung

  • Central South University
  • Natural Science Foundation of Ningxia Province
  • National Natural Science Foundation of China
  • Key Research and Development Program of Hunan Province of China
  • Xiangya Hospital, Central South University

Zitieren

APA

Wang, S., Liu, M., Shi, X., Xiong, T., Li, R., Zheng, W., Huang, Q., Nan, Y., & Ai, K. (2026). Targeting mitochondrial dysfunction to quell neuroinflammation in central nervous system (CNS): a new strategy for treating CNS disease with nanomedicines. Science Bulletin, 71(12), 3158-3195. https://doi.org/10.1016/j.scib.2026.05.020

Vancouver

Wang S, Liu M, Shi X, Xiong T, Li R, Zheng W, et al. Targeting mitochondrial dysfunction to quell neuroinflammation in central nervous system (CNS): a new strategy for treating CNS disease with nanomedicines. Science Bulletin. 2026;71(12):3158-3195. doi:10.1016/j.scib.2026.05.020

BibTeX
@article{Wang2026,
  author = {Wang, Shuya and Liu, Min and Shi, Xiaojing and Xiong, Tingli and Li, Ruishi and Zheng, Wenxuan and Huang, Qiong and Nan, Yayun and Ai, Kelong},
  title = {Targeting mitochondrial dysfunction to quell neuroinflammation in central nervous system (CNS): a new strategy for treating CNS disease with nanomedicines},
  journal = {Science Bulletin},
  year = {2026},
  volume = {71},
  number = {12},
  pages = {3158--3195},
  doi = {10.1016/j.scib.2026.05.020}
}
Kostenlos starten →